Literature DB >> 14983234

Expression of tissue factor pathway inhibitor-2 in murine and human liver regulation during inflammation.

Toru Hisaka1, Bernard Lardeux, Thierry Lamireau, Torsten Wüestefeld, Patricia F Lalor, Véronique Neaud, Patrick Maurel, Alexis Desmoulière, Walter Kisiel, Christian Trautwein, Jean Rosenbaum.   

Abstract

Tissue factor pathway inhibitor-2 (TFPI-2) is a recently described serine proteinase inhibitor. Human and murine TFPI-2 share about 50% homology. The aim of this study was to investigate the cellular localization of human and murine TFPI-2 in the liver and the regulation of their expression during acute inflammation. Northern blot, in situ hybridization and studies on isolated hepatocytes demonstrated a high-level expression of TFPI-2 in murine hepatocytes. On the other hand, very little TFPI-2 mRNA expression could be detected in human liver. Studies with isolated human liver cells suggested that TFPI-2 expression in human liver was mainly observed in liver sinusoidal endothelial cells rather than hepatocytes. Liver murine TFPI-2 expression was greatly increased after lipopolysaccharide administration with a delayed kinetics as compared to alpha1-acid glycoprotein, a classical acute-phase reactant. Accordingly, studies with isolated cells showed that the increase in TFPI-2 transcripts occurred in non-hepatocytic cells. Moreover, the LPS response was abolished in mice with a hepatocyte-specific KO for the gp130 receptor, thus indicating that a mediator from hepatocytes is involved in the up-regulation of TFPI-2 in non-parenchymal cells. In conclusion, murine TFPI-2 is highly expressed in hepatocytes in the normal murine liver and is upregulated in non-parenchymal cells in the context of inflammation. The large difference in the level of liver expression of human and murine TFPI-2 suggests that despite significant sequence similarities, these proteins presumably have different functions in the two species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983234     DOI: 10.1160/TH03-06-0358

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Genome-wide transcriptome profiling of region-specific vulnerability to oxidative stress in the hippocampus.

Authors:  Xinkun Wang; Ranu Pal; Xue-wen Chen; Keshava N Kumar; Ok-Jin Kim; Elias K Michaelis
Journal:  Genomics       Date:  2007-06-05       Impact factor: 5.736

2.  Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy.

Authors:  Yue-Zu Fan; Wei Sun
Journal:  World J Gastrointest Surg       Date:  2010-04-27

3.  The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis.

Authors:  Praveen Papareddy; Martina Kalle; Ole E Sørensen; Martin Malmsten; Matthias Mörgelin; Artur Schmidtchen
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

4.  Expression analysis of tissue factor pathway inhibitors TFPI-1 and TFPI-2 in Paralichthys olivaceus and antibacterial and anticancer activity of derived peptides.

Authors:  Guanghua Wang; Bing Xie; Yanli Su; Qinqin Gu; Dongfang Hao; Hongmei Liu; Changbiao Wang; Yonghua Hu; Min Zhang
Journal:  Vet Res       Date:  2021-02-25       Impact factor: 3.683

5.  Tissue factor pathway inhibitor 2 is found in skin and its C-terminal region encodes for antibacterial activity.

Authors:  Praveen Papareddy; Martina Kalle; Ole E Sørensen; Katarina Lundqvist; Matthias Mörgelin; Martin Malmsten; Artur Schmidtchen
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

6.  Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections.

Authors:  Gopinath Kasetty; Emanuel Smeds; Emelie Holmberg; Louise Wrange; Selvi Adikesavan; Praveen Papareddy
Journal:  BMC Microbiol       Date:  2016-06-27       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.